BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.
BCAL Diagnostics Limited has announced the commercial launch of BREASTEST plus, a first-in-class blood test for breast cancer diagnostics, marking the company’s first revenue generation. This innovative test addresses the challenge of high breast density, which affects a significant portion of women in breast cancer screening programs, and is set to be rolled out initially in Sydney and Melbourne. The launch is supported by additional patent grants, securing intellectual property protection for the technology until 2043, and positions BCAL at the forefront of blood-based breast cancer detection, potentially improving early detection and reducing unnecessary follow-ups.
More about BCAL Diagnostics Limited
BCAL Diagnostics is an Australian and US-based biotechnology company focused on advancing early and accurate breast cancer detection. The company offers innovative, non-invasive blood tests, such as the BREASTEST range, designed to complement existing breast screening methods and provide additional lipidomic insights to rule out breast cancer, thereby empowering women and clinicians with greater diagnostic confidence.
YTD Price Performance: 1.03%
Average Trading Volume: 219,629
Technical Sentiment Signal: Hold
Current Market Cap: A$35.86M
See more data about BDX stock on TipRanks’ Stock Analysis page.